Table 3.
Multivariate analyses of prognostic factors in 316 patients with stage III-IVb
| Endpoint | Variable | HR | 95% CI | P-value |
|---|---|---|---|---|
| FFS | TTV | 3.362 | 1.677–6.738 | 0.001 |
| OS | Sex | 1.735 | 0.906–3.321 | 0.096 |
| Additional boost | 1.860 | 0.947–3.654 | 0.072 | |
| Chemotherapy | 2.384 | 1.109–5.126 | 0.026 | |
| N stagea | 1.551 | 0.994–2.421 | 0.053 | |
| TTV | 4.364 | 2.125–8.964 | <0.001 | |
| DMFS | TTV | 2.923 | 1.323–6.459 | 0.008 |
| LRRFS | TTV | 2.464 | 0.951–6.383 | 0.063 |
aAccording to the 7th edition of the American Joint Commission on Cancer staging system; HR hazard ratio, CI confidence interval, FFS failure free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS loco-regional relapse free survival, TTV total tumor volume, RT radiotherapy